• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

    2/13/24 4:05:32 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care
    Get the next $GMED alert in real time by email
    SC 13G/A 1 fp0086862-25_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 1)*

     

    GLOBUS MEDICAL INC

     

    (Name of Issuer)

     

    Class A Common Stock

     

    (Title of Class of Securities)

     

    379577208

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

    [  ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 379577208   13G   Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Kayne Anderson Rudnick Investment Management, LLC

    95-4575414

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [ ]

    (b) [ ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    A California Limited Liability Company

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0 

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0 

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA 

     


     

     

    CUSIP No. 379577208   13G   Page 3 of 5 Pages

     

    Item 1. (a)

    Name of Issuer

    Globus Medical, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

    2560 General Armistead Avenue, Audubon, PA 19403

     

    Item 2. (a)

    Name of Person Filing

    Kayne Anderson Rudnick Investment Management, LLC 

         
      (b)

    Address of the Principal Office or, if none, residence

    2000 Avenue of the Stars, Suite 1110, Los Angeles, CA 90067 

         
      (c)

    Citizenship

    A California Limited Liability Company 

         
      (d)

    Title of Class of Securities

    Class A Common Stock

         
      (e)

    CUSIP Number

    379577208

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 379577208   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 0
    (b) Percent of class: 0.00%
    (c) Number of shares as to which the person has:  
      (i) Sole power to vote or to direct the vote: 0
      (ii) Shared power to vote or to direct the vote: 0
      (iii) Sole power to dispose or to direct the disposition of: 0
      (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X] .

    Instruction. Dissolution of a group requires a response to this item.

     

    The reporting person has ceased to be the beneficial owner of more than five percent of the class of securities.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A 

     

     

    CUSIP No. 379577208   13G   Page 5 of 5 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Kayne Anderson Rudnick Investment Management, LLC
         
      By:  /s/ Michael Shoemaker
      Name:  Michael Shoemaker
      Title:  Chief Compliance Officer
      Date:  February 13, 2024

     

     

    Get the next $GMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMED

    DatePrice TargetRatingAnalyst
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    8/7/2024$60.00 → $78.00Equal Weight → Overweight
    Wells Fargo
    5/20/2024$60.00 → $80.00Neutral → Overweight
    Piper Sandler
    3/18/2024$60.00Neutral → Buy
    BTIG Research
    10/20/2023$75.00Buy
    ROTH MKM
    9/19/2023$61.00Hold → Buy
    Stifel
    3/30/2023$67.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical completes acquisition of Nevro Corp.

      AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain," said Dan Scavilla, president and CEO of Globus Medical. The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal

      4/3/25 8:31:24 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    SEC Filings

    See more
    • SEC Form 10-Q filed by Globus Medical Inc.

      10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 5:19:05 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 4:16:28 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Globus Medical Inc.

      DEFA14A - GLOBUS MEDICAL INC (0001237831) (Filer)

      4/25/25 4:24:50 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Globus Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00

      1/10/25 8:55:48 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously

      12/2/24 6:57:12 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously

      8/7/24 6:47:39 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Financials

    Live finance-specific insights

    See more
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care

    $GMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/14/24 4:08:54 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 5:06:16 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 4:05:32 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics
    • Axonics® Announces Appointment of David M. Demski to Board of Directors

      IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren

      12/14/20 8:00:00 AM ET
      $AXNX
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Davidar David D

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:18:17 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Deford John A

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:15:42 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Douglas Robert Andrew

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:13:33 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care